<TEXT>&#2;<DATELINE>2003-10-12</DATELINE><TITLE>Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design</TITLE><BODY>&#3;</BODY></TEXT>